{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.01","upperLimit":".26","value":".06"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Response rate (RR) is percentage of patients whose cancer shrinks or disappears after treatment. Patients with adenoid cystic carcinoma who have a complete response (CR) or partial response (PR) per RECIST criteria v. 1.1 will be included in the results. Per RECIST v. 1.1, CR is defined as \"disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10mm.\" A PR is defined as \"At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.\"","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab and ipilimumab combination will be administered intravenously until disease progression or intolerable toxicity.\n\nNivolumab: Given at 240mg over 30 minutes (-5 / +15 minutes) every 2 weeks starting with Cycle 1 Day 1 for the first 16 weeks (1 cycle = 12 weeks). Starting with Cycle 2 Day 29, nivolumab will be given at 480mg IV over 60 minutes (-10 / +15 minutes) every 4 weeks.\n\nIpilimumab: Given at 1mg/Kg every 6 weeks starting with Cycle 1 Day 1 over approximately 90 minutes (-5 / +15 minutes).\n\nOn days when both nivolumab and ipilimumab are administered, nivolumab should be given first, followed by ipilimumab about 30 minutes after completion of nivolumab.\n\nPatients will be assessed for response every 12 weeks (±7 days).","id":"OG000","title":"Nivolumab + Ipilimumab"}],"paramType":"NUMBER","populationDescription":"Adenoid Cystic Carcinoma (ACC) patient only.","reportingStatus":"POSTED","timeFrame":"On Cycle 2 Day 1, and every cycle thereafter (1 cycle = 12 weeks), about 27 months","title":"Response Rate (RR)","type":"SECONDARY","unitOfMeasure":"percent of participants"}